Journal article
Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men
Cancer, v 127(23), pp 4403-4412
01 Dec 2021
PMID: 34347291
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background
The safety of active surveillance (AS) for African American men compared with non‐Hispanic White (White) men with intermediate‐risk prostate cancer is unclear.
Methods
The authors identified patients with modified National Comprehensive Cancer Network favorable (“low‐intermediate”) and unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer diagnosed between 2001 and 2015 and initially managed with AS in the Veterans Health Administration database. They analyzed definitive treatment, disease progression, metastases, prostate cancer–specific mortality (PCSM), and all‐cause mortality by using cumulative incidences and multivariable competing‐risks (disease progression, metastasis, and PCSM) or Cox (all‐cause mortality) regression.
Results
The cohort included 1007 men (African Americans, 330 [32.8%]; Whites, 677 [67.2%]) followed for a median of 7.7 years; 773 (76.8%) had low‐intermediate‐risk disease, and 234 (23.2%) had high‐intermediate‐risk disease. The 10‐year cumulative incidences of definitive treatment were not significantly different (African Americans, 83.5%; 95% confidence interval [CI], 78.5%‐88.7%; Whites, 80.6%; 95% CI, 76.6%‐84.4%; P = .17). Among those with low‐intermediate‐risk disease, there were no significant differences in the 10‐year cumulative incidences of disease progression (African Americans, 46.8%; 95% CI, 40.0%‐53.3%; Whites, 46.9%; 95% CI, 42.1%‐51.5%; P = .91), metastasis (African Americans, 7.1%; 95% CI, 3.7%‐11.8%; Whites, 10.8%; 95% CI, 7.6%‐14.6%; P = .17), or PCSM (African Americans, 3.8%; 95% CI, 1.6%‐7.5%; Whites, 3.8%; 95% CI, 2.0%‐6.3%; P = .69). In a multivariable regression including the entire cohort, African American race was not associated with increased risks of definitive treatment, disease progression, metastasis, PCSM, or all‐cause mortality (all P > .30).
Conclusions
Outcomes in the Veterans Affairs Health System were similar for African American and White men treated for low‐intermediate‐risk prostate cancer with AS.
The safety of active surveillance for African American men with intermediate‐risk prostate cancer is unclear. This study has measured similar clinical outcomes for African American men and non‐Hispanic White men treated for either modified National Comprehensive Cancer Network (NCCN) favorable (“low‐intermediate”) or unfavorable (“high‐intermediate”) intermediate‐risk prostate cancer with active surveillance, and it suggests that active surveillance may be an appropriate option for both African American men and non‐Hispanic White men with modified NCCN favorable (“low‐intermediate”) intermediate‐risk prostate cancer.
Metrics
Details
- Title
- Active surveillance for intermediate‐risk prostate cancer in African American and non‐Hispanic White men
- Creators
- P. Travis Courtney - Veterans Health AdministrationRishi Deka - Veterans Health AdministrationNikhil V. Kotha - Veterans Health AdministrationDaniel R. Cherry - Veterans Health AdministrationMia A. Salans - Veterans Health AdministrationTyler J. Nelson - Veterans Health AdministrationAbhishek Kumar - Veterans Health AdministrationElaine Luterstein - University of California, San DiegoAnthony T. Yip - Veterans Health AdministrationVinit Nalawade - Veterans Health AdministrationJ. Kellogg Parsons - Veterans Health AdministrationA. Karim Kader - Veterans Health AdministrationTyler F. Stewart - University of California, San DiegoBrent S. Rose - Veterans Health Administration
- Publication Details
- Cancer, v 127(23), pp 4403-4412
- Publisher
- Wiley
- Number of pages
- 10
- Grant note
- National Institutes of Health (TL1‐TR001443) Department of Defense (W81XWH‐17‐PCRP‐PRA)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Richard C. Goodwin College of Professional Studies
- Web of Science ID
- WOS:000680939000001
- Scopus ID
- 2-s2.0-85111752767
- Other Identifier
- 991021862284704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology